A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer

This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).

Criteria:

  • 18 years of age or older
  • Pancreatic cancer with a surgical treatment option
  • No prior pancreatic cancer treatments including radiation, chemotherapy, targeted therapy, investigational therapy, or surgery
  • No Gilbert's Syndrome

Locations: Hartford Hospital, Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut, MidState Medical Center, Hartford HealthCare Medical Group - Manchester, Hartford HealthCare Cancer Institute - Avon

Contacts: Hartford Region: Hayley.Dunnack@hhchealth.org 860-972-5518;
Central Region: Siobhan.Reilly@hhchealth.org 860-696-4958

Sponsor: The Alliance for Clinical Trials in Oncology

Cancer Clinical Research Office